secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001104659-24-005031
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics announces $240M underwritten offering of 21.8M shares at $11.00 each
--------------------------------------------------------------------------------

- Gross proceeds ~$240M from offering of 21.8M shares at $11.00; closing expected Jan 23, 2024.
- Proceeds to fund potential U.S. commercial launch of EDG-5506 in Becker MD, Phase 3 in Duchenne, Phase 2 trials of EDG-7500 in hypertrophic cardiomyopathy.
- New investors include RA Capital, TCGX, Venrock; existing investors Cormorant, Deerfield, Frazier, Janus, Novo, Orbimed, Perceptive, Surveyor.
- Combined cash, equivalents, and proceeds expected to exceed $500M, funding operations into 2027.
- Leerink Partners and Wedbush PacGrow acted as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924005031/0001104659-24-005031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924005031/tm243583d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-005031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer